With increasing recognition of the heterogeneity of the etiopathogenesis of Alzheimer's disease (AD), clinical and basic research has accentuated a contribution of hypothalamic dysfunction to the development of this neurodegenerative disorder. The arcuate nucleus of the hypothalamus (ARH) plays a critical role in maintaining metabolic homeostasis through its regulation of energy storage and expenditure. Although the importance of mitochondrial bioenergetics to the fitness of ARH neurons has been documented, the functional status of mitochondrial oxidative phosphorylation (OXPHOS) complexes in ARH neurons has not been comprehensively investigated in AD-related settings.
Objective
This study investigated the mitochondrial OXPHOS complex enzyme activity in ARH of AD patients.
Methods
We examined ARH mitochondrial OXPHOS complexes and AD-related pathological characteristics in AD patients. We also utilized transcriptome-wide association studies (TWAS) bioinformatics method to predict gene expression changes in ARH mitochondrial-related genes within the AD cohort.
Results
In this study, we identified mitochondrial complex IV dysfunction in tissue homogenate and synaptosomal fractions of postmortem ARH from patients with AD. Further examination determined a reverse correlation between neuronal complex IV dysfunction and ARH amyloid-β 42. Furthermore, through hypothalamus-specific TWAS analysis we identified multiple AD susceptibility genes that encode key proteins for mitochondrial OXPHOS complex assembly and function.
Conclusions
Our results suggest that ARH neuronal mitochondrial complex IV dysfunction constitutes a phenotypic change in AD that potentially contribute to ARH neuronal stress and dysmetabolism in patients with AD. These findings form a groundwork for future research to understand a hypothalamic mitochondrial pathway of AD pathogenesis.
BatraRArnoldMWorheideMA, et al.The landscape of metabolic brain alterations in Alzheimer's disease. Alzheimers Dement2023; 19: 980–998.
4.
ChenTPanFHuangQ, et al.Metabolic phenotyping reveals an emerging role of ammonia abnormality in Alzheimer's disease. Nat Commun2024; 15: 3796.
5.
KangSYKimYJJangW, et al.Body mass index trajectories and the risk for Alzheimer's disease among older adults. Sci Rep2021; 11: 3087.
6.
GustafsonDRBackmanKScarmeasN, et al.Dietary fatty acids and risk of Alzheimer's disease and related dementias: observations from the Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP). Alzheimers Dement2020; 16: 1638–1649.
7.
IkedaMBrownJHollandAJ, et al.Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer's disease. J Neurol Neurosurg Psychiatry2002; 73: 371–376.
8.
WoodfieldAPorterTGilaniI, et al.Insulin resistance, cognition and Alzheimer's disease biomarkers: evidence that CSF Abeta42 moderates the association between insulin resistance and increased CSF tau levels. Neurobiol Aging2022; 114: 38–48.
9.
YinF. Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise. FEBS J2023; 290: 1420–1453.
10.
Ravona-SpringerRSchnaider-BeeriMGoldbourtU. Body weight variability in midlife and risk for dementia in old age. Neurology2013; 80: 1677–1683.
11.
RohEHwangSYKimJA, et al.Body weight variability increases dementia risk among older adults: a nationwide population-based cohort study. Front Endocrinol (Lausanne)2020; 11: 291.
12.
SongJChoiSY. Arcuate nucleus of the hypothalamus: anatomy, physiology, and diseases. Exp Neurobiol2023; 32: 371–386.
13.
TimperKBruningJC. Hypothalamic circuits regulating appetite and energy homeostasis: pathways to obesity. Dis Model Mech2017; 10: 679–689.
14.
HahnTMBreiningerJFBaskinDG, et al.Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci1998; 1: 271–272.
15.
LeeBKimJAnT, et al.Dlx1/2 and Otp coordinate the production of hypothalamic GHRH- and AgRP-neurons. Nat Commun2018; 9: 2026.
16.
Porniece KumarMCremerALKlemmP, et al.Insulin signalling in tanycytes gates hypothalamic insulin uptake and regulation of AgRP neuron activity. Nat Metab2021; 3: 1662–1679.
17.
PintoSRoseberryAGLiuH, et al.Rapid rewiring of arcuate nucleus feeding circuits by leptin. Science2004; 304: 110–115.
18.
FernandezGCabralACornejoMP, et al.Des-acyl ghrelin directly targets the arcuate nucleus in a ghrelin-receptor independent manner and impairs the orexigenic effect of ghrelin. J Neuroendocrinol2016; 28: 12349.
19.
SrisaiDYinTCLeeAA, et al.MRAP2 Regulates ghrelin receptor signaling and hunger sensing. Nat Commun2017; 8: 713.
20.
SaperCBLowellBB. The hypothalamus. Curr Biol2014; 24: R1111–R1116.
21.
SaperCBGermanDC. Hypothalamic pathology in Alzheimer's disease. Neurosci Lett1987; 74: 364–370.
22.
IshiiMIadecolaC. Metabolic and non-cognitive manifestations of Alzheimer's disease: the hypothalamus as both culprit and target of pathology. Cell Metab2015; 22: 761–776.
23.
BaloyannisSJMavroudisIMitilineosD, et al.The hypothalamus in Alzheimer's disease: a Golgi and electron microscope study. Am J Alzheimers Dis Other Demen2015; 30: 478–487.
24.
SwaabDFGrundke-IqbalIIqbalK, et al.Tau and ubiquitin in the human hypothalamus in aging and Alzheimer's disease. Brain Res1992; 590: 239–249.
25.
SwaabDFGoudsmitEKremerHP, et al.The human hypothalamus in development, sexual differentiation, aging and Alzheimer's disease. Prog Brain Res1992; 91: 465–472.
YagitaKHondaHOharaT, et al.Association between hypothalamic Alzheimer's disease pathology and body mass index: the Hisayama study. Neuropathology2024; 44: 388–400.
28.
TrigoDAvelarCFernandesM, et al.Mitochondria, energy, and metabolism in neuronal health and disease. FEBS Lett2022; 596: 1095–1110.
29.
KannOKovacsR. Mitochondria and neuronal activity. Am J Physiol Cell Physiol2007; 292: C641–C657.
30.
TroutwineBRStropeTAFranczakE, et al.Mitochondrial function and Abeta in Alzheimer's disease postmortem brain. Neurobiol Dis2022; 171: 105781.
31.
DuHGuoLYanS, et al.Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A2010; 107: 18670–18675.
32.
WangWZhaoFMaX, et al.Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener2020; 15: 30.
33.
KapogiannisDMattsonMP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol2011; 10: 187–198.
34.
MastroeniDKhdourOMDelvauxE, et al.Nuclear but not mitochondrial-encoded oxidative phosphorylation genes are altered in aging, mild cognitive impairment, and Alzheimer's disease. Alzheimers Dement2017; 13: 510–519.
35.
KshirsagarSAlvirRVHindleA, et al.Early cellular, molecular, morphological and behavioral changes in the humanized amyloid-beta-knock-in mouse model of late-onset Alzheimer's disease. Cells2022; 11: 733.
36.
LiSWangYZhangX, et al.Mitochondrial damage-induced abnormal glucose metabolism with ageing in the hippocampus of APP/PS1 mice. Metabolomics2023; 19: 56.
37.
ReddyPH. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer's disease. CNS Spectr2009; 14: 8–13.
38.
ZorzanoAClaretM. Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction. Front Aging Neurosci2015; 7: 101.
39.
CunarroJCasadoSLugildeJ, et al.Hypothalamic mitochondrial dysfunction as a target in obesity and metabolic disease. Front Endocrinol (Lausanne)2018; 9: 283.
40.
LindforsCNilssonIAGarcia-RovesPM, et al.Hypothalamic mitochondrial dysfunction associated with anorexia in the anx/anx mouse. Proc Natl Acad Sci U S A2011; 108: 18108–18113.
41.
OhkoshiNIshiiAShiraiwaN, et al.Dysfunction of the hypothalamic-pituitary system in mitochondrial encephalomyopathies. J Med1998; 29: 13–29.
42.
ZhouXChenYIpFCF, et al.Deep learning-based polygenic risk analysis for Alzheimer's disease prediction. Commun Med (Lond)2023; 3: 49.
43.
PiweckaMRajewskyNRybak-WolfA. Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease. Nat Rev Neurol2023; 19: 346–362.
44.
JiaKTianJWangT, et al.Mitochondria-sequestered Abeta renders synaptic mitochondria vulnerable in the elderly with a risk of Alzheimer disease. JCI Insight2023; 8: e174290.
45.
SpinazziMCasarinAPertegatoV, et al.Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc2012; 7: 1235–1246.
46.
BeckSJGuoLPhensyA, et al.Deregulation of mitochondrial F1FO-ATP synthase via OSCP in Alzheimer's disease. Nat Commun2016; 7: 11483.
47.
JansenIESavageJEWatanabeK, et al.Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. Nat Genet2019; 51: 404–413.
48.
GusevAKoAShiH, et al.Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet2016; 48: 245–252.
49.
RawatPSeharUBishtJ, et al.Phosphorylated tau in Alzheimer's disease and other tauopathies. Int J Mol Sci2022; 23: 12841.
50.
RathSSharmaRGuptaR, et al.Mitocarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res2021; 49: D1541–D1547.
51.
PagliariniDJCalvoSEChangB, et al.A mitochondrial protein compendium elucidates complex I disease biology. Cell2008; 134: 112–123.
52.
TzagoloffACapitanioNNobregaMP, et al.Cytochrome oxidase assembly in yeast requires the product of COX11, a homolog of the P. denitrificans protein encoded by ORF3. EMBO J1990; 9: 2759–2764.
53.
ZetterbergHMattssonN. Understanding the cause of sporadic Alzheimer's disease. Expert Rev Neurother2014; 14: 621–630.
54.
RujeedawaTCarrillo FelezEClareICH, et al.The clinical and neuropathological features of sporadic (late-onset) and genetic forms of Alzheimer's disease. J Clin Med2021; 10: 4582.
55.
PolisBSamsonAO. Role of the metabolism of branched-chain amino acids in the development of Alzheimer's disease and other metabolic disorders. Neural Regen Res2020; 15: 1460–1470.
56.
SchiothHBCraftSBrooksSJ, et al.Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol2012; 46: 4–10.
57.
FitzpatrickALKullerLHLopezOL, et al.Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol2009; 66: 336–342.
58.
KorfHWMollerM. Arcuate nucleus, median eminence, and hypophysial pars tuberalis. Handb Clin Neurol2021; 180: 227–251.
59.
JaisABruningJC. Arcuate nucleus-dependent regulation of metabolism-pathways to obesity and diabetes mellitus. Endocr Rev2022; 43: 314–328.
60.
SamodienEPheifferCErasmusM, et al.Diet-induced DNA methylation within the hypothalamic arcuate nucleus and dysregulated leptin and insulin signaling in the pathophysiology of obesity. Food Sci Nutr2019; 7: 3131–3145.
61.
ToledanoARodriguez-CasadoAAlvarezMI, et al.Alzheimer's disease, obesity, and type 2 diabetes: focus on common neuroglial dysfunctions (critical review and new data on human brain and models). Brain Sci2024; 14: 1101.
62.
WeijieZMengZChunxiaoW, et al.Obesity-induced chronic low-grade inflammation in adipose tissue: a pathway to Alzheimer's disease. Ageing Res Rev2024; 99: 102402.
63.
ZhuangQSMengLWangZ, et al.Associations between obesity and Alzheimer's disease: multiple bioinformatic analyses. J Alzheimers Dis2021; 80: 271–281.
64.
NethBJCraftS. Insulin resistance and Alzheimer's disease: bioenergetic linkages. Front Aging Neurosci2017; 9: 345.
65.
IshiiMWangGRacchumiG, et al.Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. J Neurosci2014; 34: 9096–9106.
66.
ZhengHZhouQDuY, et al.The hypothalamus as the primary brain region of metabolic abnormalities in APP/PS1 transgenic mouse model of Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis2018; 1864: 263–273.
67.
Nolfi-DoneganDBraganzaAShivaS. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. Redox Biol2020; 37: 101674.
68.
BjorckMLBrzezinskiP. Control of transmembrane charge transfer in cytochrome c oxidase by the membrane potential. Nat Commun2018; 9: 3187.
69.
Delgado-CortesMJEspinosa-OlivaAMSarmientoM, et al.Synergistic deleterious effect of chronic stress and sodium azide in the mouse hippocampus. Chem Res Toxicol2015; 28: 651–661.
70.
WangQBingCAl-BarazanjiK, et al.Interactions between leptin and hypothalamic neuropeptide Y neurons in the control of food intake and energy homeostasis in the rat. Diabetes1997; 46: 335–341.
71.
LiebWBeiserASVasanRS, et al.Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA2009; 302: 2565–2572.
72.
NiedowiczDMStudzinskiCMWeidnerAM, et al.Leptin regulates amyloid beta production via the gamma-secretase complex. Biochim Biophys Acta2013; 1832: 439–444.
WangXYuSGaoSJ, et al.Insulin inhibits Abeta production through modulation of APP processing in a cellular model of Alzheimer's disease. Neuro Endocrinol Lett2014; 35: 224–229.
75.
RenHCookJRKonN, et al.Gpr17 in AgRP neurons regulates feeding and sensitivity to insulin and leptin. Diabetes2015; 64: 3670–3679.
76.
RonnekleivOKQiuJKellyMJ. Hypothalamic kisspeptin neurons and the control of homeostasis. Endocrinology2022; 163: bqab253.
77.
VerdileGAsihPRBarronAM, et al.The impact of luteinizing hormone and testosterone on beta amyloid (Abeta) accumulation: animal and human clinical studies. Horm Behav2015; 76: 81–90.
78.
MarboutiLZahmatkeshMRiahiE, et al.GnRH protective effects against amyloid beta-induced cognitive decline: a potential role of the 17beta-estradiol. Mol Cell Endocrinol2020; 518: 110985.
79.
FormosaLEMuellner-WongLReljicB, et al.Dissecting the roles of mitochondrial complex I intermediate assembly complex factors in the biogenesis of complex I. Cell Rep2020; 31: 107541.
80.
StroudDASurgenorEEFormosaLE, et al.Accessory subunits are integral for assembly and function of human mitochondrial complex I. Nature2016; 538: 123–126.
81.
GhezziDGoffriniPUzielG, et al.SDHAF1, Encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy. Nat Genet2009; 41: 654–656.
82.
RadinIKostLGeyU, et al.The mitochondrial copper chaperone COX11 has an additional role in cellular redox homeostasis. PLoS One2021; 16: e0261465.
83.
ZhouZZhangKLiuZ, et al.ATPAF1 Deficiency impairs ATP synthase assembly and mitochondrial respiration. Mitochondrion2021; 60: 129–141.
84.
SungAYGuerraRMSteenbergeLH, et al.Systematic analysis of NDUFAF6 in complex I assembly and mitochondrial disease. Nat Metab2024; 6: 1128–1142.
85.
PerrierSGauquelinLTetreaultM, et al.Recessive mutations in NDUFA2 cause mitochondrial leukoencephalopathy. Clin Genet2018; 93: 396–400.
86.
Van VrankenJGNaUWingeDR, et al.Protein-mediated assembly of succinate dehydrogenase and its cofactors. Crit Rev Biochem Mol Biol2015; 50: 168–180.
87.
McDuffTSumiSM. Subcortical degeneration in Alzheimer's disease. Neurology1985; 35: 123–126.
88.
LeubaGSainiK. Pathology of subcortical visual centres in relation to cortical degeneration in Alzheimer's disease. Neuropathol Appl Neurobiol1995; 21: 410–422.
89.
QiuXChenYZhouM. Two point mutations in mitochondrial DNA of cytochrome c oxidase coexist with normal mtDNA in a patient with Alzheimer's disease. Brain Res2001; 893: 261–263.
90.
OjaimiJMastersCLMcLeanC, et al.Irregular distribution of cytochrome c oxidase protein subunits in aging and Alzheimer's disease. Ann Neurol1999; 46: 656–660.
91.
HambletNSRaglandBAliM, et al.Mutations in mitochondrial-encoded cytochrome c oxidase subunits I, II, and III genes detected in Alzheimer's disease using single-strand conformation polymorphism. Electrophoresis2006; 27: 398–408.
92.
AksenovMYTuckerHMNairP, et al.The expression of several mitochondrial and nuclear genes encoding the subunits of electron transport chain enzyme complexes, cytochrome c oxidase, and NADH dehydrogenase, in different brain regions in Alzheimer's disease. Neurochem Res1999; 24: 767–774.
93.
SimonianNAHymanBT. Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J Neuropathol Exp Neurol1994; 53: 508–512.
94.
SimonianNAHymanBT. Functional alterations in Alzheimer's disease: diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol1993; 52: 580–585.
95.
DwyerBEStoneMLGormanN, et al.Heme-a, the heme prosthetic group of cytochrome c oxidase, is increased in Alzheimer's disease. Neurosci Lett2009; 461: 302–305.
96.
CrouchPJBlakeRDuceJA, et al.Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci2005; 25: 672–679.
97.
Hernandez-ZimbronLFLuna-MunozJMenaR, et al.Amyloid-beta peptide binds to cytochrome C oxidase subunit 1. PLoS One2012; 7: e42344.
98.
XuYChengLSunJ, et al.Hypermethylation of mitochondrial cytochrome b and cytochrome c oxidase II genes with decreased mitochondrial DNA copy numbers in the APP/PS1 transgenic mouse model of Alzheimer's disease. Neurochem Res2021; 46: 564–572.
99.
ReddyPH. Amyloid beta, mitochondrial structural and functional dynamics in Alzheimer's disease. Exp Neurol2009; 218: 286–292.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
